Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | Developing novel biomarkers in MS: diagnostic, predictive, & prognostic

Jeffrey Cohen • 24 Feb 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Jeffrey A. Cohen, MD, Cleveland Clinic, Cleveland, OH, comments on the common goals of researchers in the multiple sclerosis (MS) space; to develop quantitative, objective, and clinically useful biomarkers. Various types of biomarkers are under investigation to improve numerous aspects of MS diagnosis and management, including markers that can predict an individual’s risk of disease development, enable accurate disease monitoring, and give novel insights into disease processes. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Jeffrey Cohen

Key remaining questions regarding HSCT in MS: procedure and effectiveness in treating PIRA
2:33
Key remaining questions regarding HSCT in MS: procedure and effectiveness in treating PIRA
Jeffrey Cohen • 11 Feb 2026
HSCT versus high-efficacy therapies in multiple sclerosis: the BEAT-MS trial
2:09
HSCT versus high-efficacy therapies in multiple sclerosis: the BEAT-MS trial
Jeffrey Cohen • 11 Feb 2026
HSCT in multiple sclerosis: current evidence and patient selection
3:03
HSCT in multiple sclerosis: current evidence and patient selection
Jeffrey Cohen • 11 Feb 2026
Ozanimod: long-term safety and efficacy in relapsing MS
1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen • 24 Feb 2022

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals